CIK 0001293971
BLUE bluebird bio, Inc.
Insider trading from SEC Form 4. Last filing Jun 3, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Signals
Open-market buys and sells at bluebird bio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 3Weak | Richard A Colvin Chief Medical Officer sell | $2,289 584 shares | -7% | - | |
| 3Weak | Thomas J Klima See Remarks sell | $1,960 500 shares | -6% | - | |
| 3Weak | Richard A Colvin Chief Medical Officer sell | $473 64 shares | -1% | - | |
| 3Weak | Thomas J Klima See Remarks sell | $902 122 shares | -1% | - | |
| 0Weak | Richard A Colvin Chief Medical Officer sell | $176 19 shares | -0% | - | |
| 3Weak | Richard A Colvin Chief Medical Officer sell | $1,178 2,824 shares | -2% | - | |
| 13Weak | Andrew Obenshain President and CEO sell | $405 971 shares | -0% | - |
Transactions
The last 57 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 2, 2025 | Michael Cloonan director | DDisposition to issuer Common Stock | -1,867 | - | - | 0 | Jun 3, 2025 |
| May 30, 2025 | Joseph Vittiglio Chief Business & Legal Officer | UTender of shares Common Stock | -1,143 | - | - | 3,125 | Jun 3, 2025 |
| May 30, 2025 | Mark Vachon director | UTender of shares Common Stock | -1,252 | - | - | 1,245 | Jun 3, 2025 |
| May 30, 2025 | Najoh Tita-Reid director | UTender of shares Common Stock | -1,163 | - | - | 1,245 | Jun 3, 2025 |
| May 30, 2025 | Richard A. Paulson director | UTender of shares Common Stock | -155 | - | - | 1,323 | Jun 3, 2025 |
| May 30, 2025 | Andrew Obenshain President and CEO | UTender of shares Common Stock | -9,027 | - | - | 9,300 | Jun 3, 2025 |
| May 30, 2025 | Nick Leschly director | UTender of shares Common Stock | -14,416 | - | - | 1,245 | Jun 3, 2025 |
| May 30, 2025 | Elisabeth Leiderman director | UTender of shares Common Stock | -1,112 | - | - | 1,245 | Jun 3, 2025 |
| May 30, 2025 | Thomas J Klima See Remarks | UTender of shares Common Stock | -3,414 | - | - | 4,464 | Jun 3, 2025 |
| May 30, 2025 | Charlotte Jones-Burton director | UTender of shares Common Stock | -928 | - | - | 1,245 | Jun 3, 2025 |
| May 30, 2025 | Richard A Colvin Chief Medical Officer | UTender of shares Common Stock | -3,552 | - | - | 4,166 | Jun 3, 2025 |
| May 30, 2025 | John O Agwunobi director | UTender of shares Common Stock | -1,323 | - | - | 1,245 | Jun 3, 2025 |
| Jun 2, 2025 | O. James Sterling Chief Financial Officer | DDisposition to issuer Common Stock | -5,000 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | Richard A. Paulson director | DDisposition to issuer Common Stock | -1,323 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | John O Agwunobi director | DDisposition to issuer Common Stock | -1,245 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | Richard A Colvin Chief Medical Officer | DDisposition to issuer Common Stock | -4,166 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | Charlotte Jones-Burton director | DDisposition to issuer Common Stock | -1,245 | - | - | 0 | Jun 3, 2025 |
| May 30, 2025 | Nick Leschly director | UTender of shares Common Stockindirect: Nick Leschly 2001 Trust | -2,284 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | Thomas J Klima See Remarks | DDisposition to issuer Common Stock | -4,464 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | Elisabeth Leiderman director | DDisposition to issuer Common Stock | -1,245 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | Andrew Obenshain President and CEO | DDisposition to issuer Common Stock | -9,300 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | Joseph Vittiglio Chief Business & Legal Officer | DDisposition to issuer Common Stock | -3,125 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | Mark Vachon director | DDisposition to issuer Common Stock | -1,245 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | O. James Sterling Chief Financial Officer | AGrant or award Common Stock | +2,500 | - | - | 2,500 | Jun 3, 2025 |
| Jun 2, 2025 | Najoh Tita-Reid director | DDisposition to issuer Common Stock | -1,245 | - | - | 0 | Jun 3, 2025 |
| May 30, 2025 | Nick Leschly director | UTender of shares Common Stockindirect: Nick Leschly Irrevocable GST Trust of 2019 | -6,150 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | Joseph Vittiglio Chief Business & Legal Officer | AGrant or award Common Stock | +2,500 | - | - | 2,500 | Jun 3, 2025 |
| Jun 2, 2025 | Andrew Obenshain President and CEO | AGrant or award Common Stock | +14,820 | - | - | 14,820 | Jun 3, 2025 |
| Jun 2, 2025 | Richard A Colvin Chief Medical Officer | AGrant or award Common Stock | +2,500 | - | - | 2,500 | Jun 3, 2025 |
| Jun 2, 2025 | O. James Sterling Chief Financial Officer | DDisposition to issuer Common Stock | -2,500 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | Thomas J Klima See Remarks | AGrant or award Common Stock | +2,500 | - | - | 2,500 | Jun 3, 2025 |
| Jun 2, 2025 | Richard A Colvin Chief Medical Officer | DDisposition to issuer Common Stock | -2,500 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | Thomas J Klima See Remarks | DDisposition to issuer Common Stock | -2,500 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | Nick Leschly director | DDisposition to issuer Common Stock | -1,245 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | Andrew Obenshain President and CEO | DDisposition to issuer Common Stock | -14,820 | - | - | 0 | Jun 3, 2025 |
| Jun 2, 2025 | Joseph Vittiglio Chief Business & Legal Officer | DDisposition to issuer Common Stock | -2,500 | - | - | 0 | Jun 3, 2025 |
| Mar 3, 2025 | Richard A Colvin Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -584 | $3.92 | $2,289 | 7,610 | Mar 5, 2025 |
| Mar 3, 2025 | Thomas J Klima See Remarks | SOpen-market sale Common Stock10b5-1 | -500 | $3.92 | $1,960 | 7,878 | Mar 5, 2025 |
| Feb 3, 2025 | Thomas J Klima See Remarks | SOpen-market sale Common Stock10b5-1 | -122 | $7.39 | $902 | 8,378 | Feb 5, 2025 |
| Feb 3, 2025 | Richard A Colvin Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -64 | $7.39 | $473 | 8,194 | Feb 5, 2025 |
| Jan 6, 2025 | Richard A Colvin Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -19 | $9.24 | $176 | 8,257 | Jan 8, 2025 |
| Dec 10, 2024 | Richard A Colvin Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -2,824 | $0.42 | $1,178 | 165,544 | Dec 12, 2024 |
| Dec 10, 2024 | Andrew Obenshain President and CEO | SOpen-market sale Common Stock10b5-1 | -971 | $0.42 | $405 | 374,247 | Dec 12, 2024 |
| Nov 6, 2024 | John O Agwunobi director | AGrant or award Common Stock | +24,900 | $0.00 | $0 | 51,364 | Nov 8, 2024 |
| Nov 6, 2024 | Charlotte Jones-Burton director | AGrant or award Common Stock | +24,900 | $0.00 | $0 | 43,462 | Nov 8, 2024 |
| Nov 6, 2024 | Mark Vachon director | AGrant or award Common Stock | +24,900 | $0.00 | $0 | 49,941 | Nov 8, 2024 |
| Nov 6, 2024 | Elisabeth Leiderman director | AGrant or award Common Stock | +24,900 | $0.00 | $0 | 47,156 | Nov 8, 2024 |
| Nov 6, 2024 | Nick Leschly director | AGrant or award Common Stock | +24,900 | $0.00 | $0 | 315,839 | Nov 8, 2024 |
| Nov 6, 2024 | Najoh Tita-Reid director | AGrant or award Common Stock | +24,900 | $0.00 | $0 | 48,160 | Nov 8, 2024 |
| Nov 6, 2024 | Richard A. Paulson director | AGrant or award Common Stock | +24,900 | $0.00 | $0 | 29,563 | Nov 8, 2024 |
| Nov 6, 2024 | Mark Vachon director | AGrant or award Stock Option (right to buy)derivative | +49,850 | $0.00 | $0 | 49,850 | Nov 8, 2024 |
| Nov 6, 2024 | Najoh Tita-Reid director | AGrant or award Stock Option (right to buy)derivative | +49,850 | $0.00 | $0 | 49,850 | Nov 8, 2024 |
| Nov 6, 2024 | Richard A. Paulson director | AGrant or award Stock Option (right to buy)derivative | +49,850 | $0.00 | $0 | 49,850 | Nov 8, 2024 |
| Nov 6, 2024 | Elisabeth Leiderman director | AGrant or award Stock Option (right to buy)derivative | +49,850 | $0.00 | $0 | 49,850 | Nov 8, 2024 |
| Nov 6, 2024 | Charlotte Jones-Burton director | AGrant or award Stock Option (right to buy)derivative | +49,850 | $0.00 | $0 | 49,850 | Nov 8, 2024 |
| Nov 6, 2024 | John O Agwunobi director | AGrant or award Stock Option (right to buy)derivative | +49,850 | $0.00 | $0 | 49,850 | Nov 8, 2024 |
| Nov 6, 2024 | Nick Leschly director | AGrant or award Stock Option (right to buy)derivative | +49,850 | $0.00 | $0 | 49,850 | Nov 8, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- John O Agwunobidirector
- Michael Cloonanceo, president, officer, director
- Richard A ColvinChief Medical Officer
- Charlotte Jones-Burtondirector
- Thomas J KlimaSee Remarks
- Elisabeth Leidermandirector
- Nick Leschlydirector
- Andrew ObenshainPresident and CEO
- Richard A. Paulsonceo, president, officer, director
- O. James SterlingChief Financial Officer
- Najoh Tita-Reiddirector
- Mark Vachondirector
- Joseph VittiglioChief Business & Legal Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.